Related Experiment Videos
Is metronidazole carcinogenic?
Andrés Bendesky1, Daniel Menéndez, Patricia Ostrosky-Wegman
1Facultad de Medicina, Universidad Nacional Autónoma de México, DF, México.
Mutation Research
|June 8, 2002
Summary
Metronidazole (MTZ) is a widely used drug that shows mutagenic and carcinogenic properties in lab studies and animals. However, current human studies are insufficient to confirm its cancer risk in people.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Metronidazole (MTZ) is a globally utilized antiparasitic and antibacterial agent.
- Evidence suggests MTZ is potentially carcinogenic, mutagenic in bacteria, genotoxic to human cells, and carcinogenic in animals.
- Despite this evidence, MTZ is not classified as a human cancer risk due to insufficient epidemiological data.
Purpose of the Study:
- To evaluate the carcinogenic potential of Metronidazole (MTZ) in humans.
- To highlight the limitations of existing epidemiological studies on MTZ's cancer risk.
- To emphasize the need for improved research into MTZ's genotoxicity and carcinogenicity.
Main Methods:
- Review and critique of existing population studies on Metronidazole (MTZ) and human cancer.
- Analysis of mutagenic, genotoxic, and animal carcinogenicity data for MTZ.
- Discussion of potential confounding factors in human studies, such as individual sensitivity.
Main Results:
- Existing epidemiological studies on MTZ are limited by small sample sizes and insufficient follow-up periods.
- Individual sensitivity to MTZ may act as a confounding factor in population studies.
- The carcinogenic potential of MTZ in humans remains uncertain due to methodological flaws in current research.
Conclusions:
- Metronidazole (MTZ) exhibits properties suggesting carcinogenic potential.
- Current human studies are inadequate to definitively assess MTZ's cancer risk.
- Further rigorous epidemiological studies are required to elucidate MTZ's genotoxicity and carcinogenic effects in humans.